Lilly leaps on positive outlook as it 'moves past negative solanezumab data'

15 December 2016

Shares in US pharma major Eli Lilly (NYSE: LLY) were up by 4%, at $70.51 by lunchtime on Thursday, following the company’s announcement of its 2017 financial guidance and outlook for the next decade.

It has not been an easy few weeks for Lilly, which announced the failure of solanezumab, its lead candidate for Alzheimer’s disease, in a Phase III trial, in late November. This news sent the company’s stock value plummeting by 12.5% within hours. It was then reported last week that the company was planning to cut hundreds of jobs.

"As we move past the negative solanezumab data read-out, Lilly's innovation-based strategy is generating strong momentum in multiple therapeutic areas"

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK